Germany: BioNTech Shutting Down COVID Vaccine Production

TEMPO.CO, Jakarta - The Mainz-based company BioNTech that shot to global notoriety amid the COVID-19 pandemic for its work on one of the first mRNA coronavirus vaccines has announced drastic restructuring plans. 

As reported by DW, the company is winding down its COVID vaccine production entirely, leaving the production to its U.S. partner, Pfizer, going forward.

"In the course of this year we will produce the last doses here in Germany," a company spokeswoman told the Reuters news agency. 

What is closing down and how many jobs could be at risk? 

Amid the restructuring, the company is closing production centers in Idar-Oberstein, in Marburg, in Singapore, in Asia, and another German facility in Tubingen, belonging to the CureVac rival company that BioNTech fully took over as of late 2025 after a lengthy acquisition process.

The company said that the closures should be completed by the end of 2027, and that it would look into possibilities to sell the affected facilities. 

BioNTech said last year that it would be cutting between 950 and 1,350 full-time jobs over the subsequent two years — it's not clear how many it had already cut. The company says that up to 1,860 jobs could be affected in total amid the expanded restructuring. 

Why is BioNTech moving away from COVID treatment and towards cancer research, currently at great cost?

BioNTech said that it was reacting to a marked decline in demand for COVID vaccines. For a brief period at the height of the pandemic, these were recommended to almost anybody for regular renewal, but they now tend to be administered mainly to the elderly and other high-risk people.

In Germany, BioNTech plans to keep its main base in Mainz, as well as office facilities only in Berlin and Munich. The company has retooled to return its focus primarily to research, on treating cancer and other illnesses.

The company logged falling revenues of €118.1 million (roughly $138 million) in the first quarter of this year, compared to €182.8 in the same period in 2025.

Meanwhile, its net losses for the year rose to €531.9 million. These costs were attributed to investments in research and development costs — not least for an antibody called Pumitamig which the company hopes can have multi-purpose usage in cancer treatment and which is currently in global phase 2 trials. 

BioNTech's founders Ugur Sahin and Ozlem Tureci announced in March that they were stepping down to start a new venture. 

Read: Understanding Hantavirus: Symptoms, Causes, and Risks

Click here to get the latest news updates from Tempo on Google News

Fact Check: Claim Vaccine Industry Deliberately Makes Children Sick Is False

7 hari lalu

Government Struggles to Contain the Measles Outbreak

14 hari lalu

Indonesia Expands HPV Vaccine Program to Include Men Starting 2026

14 hari lalu

Slow Measles Response

14 hari lalu

BPOM Approves Measles Vaccine for Adults amid Case Surge

25 hari lalu

Fact Check: Cancer Cure Not Linked to US-WHO Exit

1 Maret 2026

Fact Check: Claim That the Covid-19 Pandemic Never Happened Is False

23 Februari 2026

Fact Check: No, AstraZeneca Vaccine Does Not Mean 'Path to Death'

22 Februari 2026

How Fast Is Influenza A(H3N2) Subclade K Spreading in Indonesia?

2 Januari 2026

Indonesia Designated as a WHO Listed Authority

24 Desember 2025